Vitiligo: An update on current pharmacotherapy and future directions

Expert Opinion on Pharmacotherapy

Volumn 13, Issue 13, 2012, Pages 1885-1899

  Colucci, Roberta ^a   Lotti, Torello ^b   Moretti, Silvia ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

^b UNIVERSITY OF ROME G MARCONI   (Italy)

Author keywords

Antioxidants; Calcineurin inhibitors; Combination therapy; Corticosteroids; Depigmentation; Immunosuppressant drugs; Photochemotherapy; Vitiligo

Indexed keywords

ALPHA TOCOPHEROL; ASCORBIC ACID; BERGAPTEN; BETAMETHASONE; CALCINEURIN INHIBITOR; CALCIPOTRIOL; CALCIUM; CATALASE; CLOBETASOL PROPIONATE; CORTICOSTEROID; DEPIGMENTING AGENT; DEXAMETHASONE; FLUTICASONE PROPIONATE; HYDROCORTISONE BUTYRATE; HYDROQUINONE DERIVATIVE; IMMUNOSUPPRESSIVE AGENT; KHELLIN; METHOXSALEN DERIVATIVE; METHYLPREDNISOLONE ACEPONATE; MOMETASONE FUROATE; PHENYLALANINE; PIMECROLIMUS; PLACEBO; PREDNISOLONE; PROSTAGLANDIN E; PSORALEN; TACROLIMUS; TRIMETHYLPSORALEN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VITAMIN D DERIVATIVE; VITIX;

ACNE; AGITATION; BLISTER; BURN; BURNING SENSATION; CANCER RISK; CLIMATOTHERAPY; CLINICAL TRIAL (TOPIC); DRUG EFFICACY; DRUG MECHANISM; DRUG PULSE THERAPY; DRUG SAFETY; DRUG TOLERABILITY; ECZEMA; ERYTHEMA; EXCIMER LASER; EYE TOXICITY; FLUSHING; FOLLICULITIS; GRAFT FAILURE; HEADACHE; HUMAN; HYPERPIGMENTATION; HYPERTRICHOSIS; INSOMNIA; KELOID; LIVER TOXICITY; MELANOCYTE; MELANOGENESIS; MELANOMA; MENSTRUATION DISORDER; MERKEL CELL TUMOR; META ANALYSIS (TOPIC); MONOTHERAPY; NAUSEA; NEPHROTOXICITY; NON MELANOMA SKIN CANCER; PHOTOAGING; PHOTOCHEMOTHERAPY; PHOTOSENSITIVITY DISORDER; PHOTOTHERAPY; POSTOPERATIVE COMPLICATION; POSTOPERATIVE INFECTION; PRURITUS; PUVA; RECURRENT DISEASE; REVIEW; SCAR FORMATION; SIDE EFFECT; SKIN ABRASION; SKIN ATROPHY; SKIN BURNING SENSATION; SKIN IRRITATION; SKIN LYMPHOMA; STRIA; SWEATING; TELANGIECTASIA; THERAPY; TREATMENT INDICATION; ULTRAVIOLET A RADIATION; ULTRAVIOLET B RADIATION; VITILIGO; WEIGHT GAIN;

ANIMALS; ANTIOXIDANTS; DERMATOLOGIC AGENTS; HUMANS; PHOTOCHEMOTHERAPY; PHOTOTHERAPY; SKIN LIGHTENING PREPARATIONS; SKIN PIGMENTATION; TREATMENT OUTCOME; VITILIGO;

EID: 84865336586     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2012.712113     Document Type: Review

References (166)

1. Spritz RA. Recent progress in the genetics of generalized vitiligo. J Genet Genomics 2011;38:271-8 (Pubitemid 47057312)
2. Schallreuter KU, Bahadoran P, Picardo M, et al. Vitiligo pathogenesis: autoimmune disease, genetic defect, excessive reactive oxygen species, calcium imbalance, or what else? Exp Dermatol 2008;17:139-40
3. Sandoval-Cruz M, Garćia-Carrasco M, Sánchez-Porras R, et al. Immunopathogenesis of vitiligo. Autoimmun Rev 2011;10:762-5
4. Eskandani M, Golchai J, Pirooznia N, et al. Oxidative stress level and tyrosinase activity in vitiligo patients. Indian J Dermatol 2010;55:15-19
5. Al Abadie MSK, Senior HI, Bleehen SS, et al. Neuropeptide and neuronal marker studies in vitiligo. Br J Dermatol 1994;131:160-5 (Pubitemid 24251486)
6. Moretti S, Spallanzani A, Amato L, et al. New insights into the pathogenesis of vitiligo: imbalance of epidermal cytokines at sites of lesions. Pigment Cell Res 2002;15:87-92 (Pubitemid 34536320)
7. Moretti S, Spallanzani A, Amato L, et al. Vitiligo and epidermal microenvironment: possible involvement of keratinocyte-derived cytokines. Arch Dermatol 2002;138:273-4 (Pubitemid 34160415)
8. Birol A, Kisa U, Kurtipek GS, et al. Increased tumor necrosis factor alpha (TNF-alpha) and interleukin 1 alpha (IL1-alpha) levels in the lesional skin of patients with nonsegmental vitiligo. Int J Dermatol 2006;45:992-3 (Pubitemid 44145043)
9. Gauthier Y, Cario Andre M, Taïeb A. A critical appraisal of vitiligo etiologic theories. Is melanocyte loss a melanocytorrhagy? Pigment Cell Res 2003;16:322-32 (Pubitemid 36950564)
10. Taïeb A. Vitiligo as an inflammatory skin disorder: a therapeutic perspective. Pigment Cell Melanoma Res 2012;25:9-13
11. Ezzedine K, Lim HW. Suzuki T, et al.; on behalf of the Vitiligo Global Issue Consensus Conference panelists. Revised classification/nomenclature of vitiligo and related issues: the vitiligo global issues consensus conference. Pigment Cell Melanoma Res 2012;25:E1-E13
12. Cheng YP, Chiu HY, Jee SH, Tsai TF. Excimer light photototherapy of segmental and non-segmental vitiligo: experience in Taiwan. Photodermatol Photoimmunol Photomed 2012;28:6-11
13. Kathuria S, Khaitan BK, Ramam M, Sharma VK. Segmental vitiligo: a randomized controlled trial to evaluate efficacy and safety of 0.1% tacrolimus ointment vs 0.05% fluticasone propionate cream. Indian J Dermatol Venereol Leprol 2012;78:68-73
14. Do JE, Shin JY, Kim DY, et al. The effect of 308 nm excimer laser on segmental vitiligo: a retrospective study of 80 patients with segmental vitiligo. Photodermatol Photoimmunol Photomed 2011;27:147-51
15. Lee DY, Kim CR, Park JH, Lee JH. The incidence of leukotrichia in segmental vitiligo: implication of poor response to medical treatment. Int J Dermatol 2011;50:925-7
16. Ezzedine K, Gauthier Y, Léauté-Labrèze C, et al. Segmental vitiligo associated with generalized vitiligo (mixed vitiligo): a retrospective case series of 19 patients. J Am Acad Dermatol 2011;65:965-71
17. Taieb A, Picardo M; VETF members. The definition and assessment of vitiligo: a consensus report of the Vitiligo European Task Force. Pigment Cell Res 2007;20:27-35 (Pubitemid 46090162)
18. Falabella R. Vitiligo and the melanocyte reservoir. Indian J Dermatol 2009;54:313-18
19. Cui J, Shen LY, Wang GC. Role of hair follicles in the repigmentation of vitiligo. J Invest Dermatol 1991;97:410-16
20. Nishimura EK. Melanocyte stem cells: a melanocyte reservoir in hair follicles for hair and skin pigmentation. Pigment Cell Melanoma Res 2011;24:2401-10
21. Ortonne JP, Schmitt D, Thivolet J. PUVA-induced repigmentation of vitiligo: scanning electron microscopy of hair follicles. J Invest Dermatol 1980;74:40
22. Nishimura EK, Jordan SA, Oshima H, et al. Dominant role of the niche in melanocyte stem-cell fate determination. Nature 2002;416:854-60 (Pubitemid 34453742)
23. Hoerter JD, Bradley P, Casillas A, et al. Extrafollicular dermal melanocyte stem cells and melanoma. Stem Cells Int 2012;Published online 10 May 2012; doi:2012:407079
24. Felsten LM, Alikhan A, Petronic-Rosic V. Vitiligo: a comprehensive overview part II: treatment options and approach to treatment. J Am Acad Dermatol 2011;65:493-514
25. Bleehen SS. The treatment of vitiligo with topical corticosteroids. Light and electronmicroscopic studies. Br J Dermatol 1976;94:43-50
26. Tadicherla S, Ross K, Shenefelt PD, Fenske NA. Topical corticosteroids in dermatology. J Drugs Dermatol 2009;8:1093-105
27. Njoo MD, Spuls PI, Bos JD, et al. Nonsurgical repigmentation therapies in vitiligo. Meta-analysis of the literature. Arch Dermatol 1998;134:1532-40 (Pubitemid 29009253)
28. Kwinter J, Pelletier J, Khambalia A, et al. High-potency steroid use in children with vitiligo: a retrospective study. J Am Acad Dermatol 2007;56:236-41 (Pubitemid 46074239)
29. Ho N, Pope E, Weinstein M, et al. A double-blind, randomized, placebo-controlled trial of topical tacrolimus 0•1% vs. clobetasol propionate 0•05% in childhood vitiligo. Br J Dermatol 2011;165:626-32
30. Cockayne SE, Messenger AG, Gawkrodger DJ. Vitiligo treated with topical corticosteroids: children with head and neck involvement respond well. J Am Acad Dermatol 2002;46:964-5
31. Sassi F, Cazzaniga S, Tessari G, et al. Randomized controlled trial comparing the effectiveness of 308-nm excimer laser alone or in combination with topical hydrocortisone 17-butyrate cream in the treatment of vitiligo of the face and neck. Br J Dermatol 2008;159:1186-91
32. Westerhof W, Nieuweboer-Krobotova L, Mulder PG, et al. Left-right comparison study of the combination of fluticasone propionate and UV-A vs. either fluticasone propionate or UV-A alone for the long-term treatment of vitiligo. Arch Dermatol 1999;135:1061-6 (Pubitemid 29430496)
33. Bayoumi W, Fontas E, Sillard L, et al. Effect of a preceding laser dermabrasion on the outcome of combined therapy with narrowband ultraviolet B and potent topical steroids for treating nonsegmental vitiligo in resistant localizations. Br J Dermatol 2012;166:208-11
34. Chan S, Gerson B, Subramaniam S. The role of copper, molybdenum, selenium, and zinc in nutrition and health. Clin Lab Med 1998;18:673-85 (Pubitemid 28531294)
35. Shibata T, Prota G, Mishima Y. Non-melanosomal regulatory factors in melanogenesis. J Invest Dermatol 1993;100:274S-80S (Pubitemid 23083173)
36. Yaghoobi R, Omidian M, Bagherani N. Comparison of therapeutic efficacy of topical corticosteroid and oral zinc sulfate-topical corticosteroid combination in the treatment of vitiligo patients: a clinical trial. BMC Dermatol 2011;11:7
37. Grimes PE, Morris R, Avaniss-Aghajani E, et al. Topical tacrolimus therapy for vitiligo: therapeutic responses and skin messenger RNA expression of proinflammatory cytokines. J Am Acad Dermatol 2004;51:52-61 (Pubitemid 38887475)
38. Shi F, Erf GF. IFN-g, IL-21, and IL-10 co-expression in evolving autoimmune vitiligo lesions of Smyth line chickens. J Invest Dermatol 2012;132:642-9
39. Lan CC, Chen GS, Chiou MH, et al. FK506 promotes melanocyte and melanoblast growth and creates a favourable milieu for cell migration via keratinocytes: possible mechanisms of how tacrolimus ointment induces repigmentation in patients with vitiligo. Br J Dermatol 2005;153:498-505
40. Lee KY, Jeon SY, Hong JW, et al. Endothelin-1 enhances the proliferation of normal human melanocytes in a paradoxical manner from the TNF-a-inhibited condition, but tacrolimus promotes exclusively the cellular migration without proliferation: a proposed action mechanism for combination therapy of phototherapy and topical tacrolimus in vitiligo treatment. J Eur Acad Dermatol Venereol 2012;Published online 9 Mar 2012; doi: 10.1111/j.1468-3083.2012.04498.x
41. Udompataikul M, Boonsupthip P, Siriwattanagate R. Effectiveness of 0.1% topical tacrolimus in adult and children patients with vitiligo. J Dermatol 2011;38:536-40
42. Silverberg JI, Silverberg NB. Topical tacrolimus is more effective for treatment of vitiligo in patients of skin of color. J Drugs Dermatol 2011;10:507-10
43. Juan D, Qianxi X, Zhou C, Jianzhong Z. Clinical efficacy and safety of tacrolimus ointment in patients with vitiligo. J Dermatol 2011;38:1092-4
44. Nisticò S, Chiricozzi A, Saraceno R, et al. Vitiligo treatment with monochromatic excimer light and tacrolimus: results of an open randomized controlled study. Photomed Laser Surg 2012;30:26-30
45. Lotti T, Buggiani G, Troiano M, et al. Targeted and combination treatments for vitiligo. Comparative evaluation of different current modalities in 458 subjects. J Dermatol Ther 2008;21:S20-6 (Pubitemid 352033058)
46. Stinco G, Piccirillo F, Sallustio M, Patrone P. Facial flush reaction after alcohol ingestion during topical pimecrolimus and tacrolimus treatment. Dermatology 2009;218:71-2
47. Ring J, Möhrenschlager M, Henkel V. The US FDA 'black box' warning for topical calcineurin inhibitors: an ongoing controversy. Drug Saf 2008;31:185-98 (Pubitemid 351311575)
48. Guideline on Vitiligo. Developed by the guideline subcommittee "Vitiligo" of the European Dermatologic Forum. Available from: http://www.sidemast.org/download/sidemast-20120227103850.pdf [Last Accessed 25 April 2012]
49. De Francesco V, Stinco G, Laspina S, et al. Immunohistochemical study before and after narrow band (311 nm) UVB treatment in vitiligo. Eur J Dermatol 2008;18:292-6 (Pubitemid 351821232)
50. Wu CS, Lan CC, Wang LF, et al. Effects of psoralen plus ultraviolet A irradiation on cultured epidermal cells in vitro and patients with vitiligo in vivo. Br J Dermatol 2007;156:122-9
51. Yones SS, Palmer RA, Garibaldinos TM, Hawk JL. Randomized double-blind trial of treatment of vitiligo: efficacy of psoralen-UV-A therapy vs narrowband-UV-B therapy. Arch Dermatol 2007;143:578-84 (Pubitemid 46799844)
52. Arca E, Tastan HB, Erbil AH, et al. Narrow-band ultraviolet B as monotherapy and in combination with topical calcipotriol in the treatment of vitiligo. J Dermatol 2006;33:338-43 (Pubitemid 43943367)
53. Kanwar AJ, Dogra S. Narrow-band UVB for the treatment of generalized vitiligo in children. Clin Exp Dermatol 2005;30:332-6 (Pubitemid 40835321)
54. Kanwar AJ, Dogra S, Parsad D, Kumar B. Narrow-band UVB for the treatment of vitiligo: an emerging effective and well tolerated therapy. Int J Dermatol 2005;44:57-60 (Pubitemid 40201994)
55. Dell'Anna ML, Mastrofrancesco A, Sala R, et al. Antioxidants and narrow band UVB in the treatment of vitiligo: a double blind placebo controlled trial. Clin Exp Dermatol 2007;32:631-6
56. Gamil H, Attwa E, Ghonemy S. Narrowband ultraviolet B as monotherapy and in combination with topical calcipotriol in the treatment of generalized vitiligo. Clin Exp Dermatol 2010;35:919-21
57. Bakis-Petsoglou S, Le Guay JL, Wittal R. A randomized, double-blinded, placebo-controlled trial of pseudocatalase cream and narrowband ultraviolet B in the treatment of vitiligo. Br J Dermatol 2009;161:910-17
58. Bhatnagar A, Kanwar AJ, Parsad D, De D. Comparison of systemic PUVA and NB-UVB in the treatment of vitiligo: an open prospective study. J. Eur Acad Dermatol Venereol 2007;21:638-42 (Pubitemid 46916761)
59. Parsad D, Kanwar AJ, Kumar B. Psoralen-ultraviolet A vs. narrow-band ultraviolet B phototherapy for the treatment of vitiligo. J Eur Acad Dermatol Venereol 2006;20:175-7 (Pubitemid 43740518)
60. Archier E, Devaux S, Castela E, et al. Carcinogenic risks of psoralen UV-A therapy and narrowband UV-B therapy in chronic plaque psoriasis: a systematic literature review. J Eur Acad Dermatol Venereol 2012;26(S3):22-31
61. Pacifico A, Leone G. Photo(chemo) therapy for vitiligo. Photodermatol Photoimmunol Photomed 2011;27:261-7
62. Kao CH, Yu HS. Depletion and repopulation of Langerhans cells in non segmental type vitiligo. J Dermatol 1990;17:287-96
63. Kao CH, Yu HS. Effects of PUVA on melanocytes in vitiligo and in patients with vitiligo vulgaris. J Invest Dermatol 1992;98:734-40
64. Lei TC, Virador V, Yasumoto K, et al. Stimulation of melanoblast pigmentation by 8-methoxypsoralen: the involvement of microphthalmia-associated transcription factor, the protein kinase A signal pathway, and proteasome-mediated degradation. J Invest Dermatol 2002;119:1341-9 (Pubitemid 36005618)
65. Abdel-Naser MB, Hann SK, Bystryn JC. Oral psoralen with UV-A therapy releases circulating growth factor(s) that stimulates cell proliferation. Arch Dermatol 1997;133:1530-3 (Pubitemid 27525731)
66. Mai DW, Omohundro C, Dijkstra JW, et al. Childhood vitiligo successfully treated with bath PUVA. Pediatr Dermatol 1998;15:53-5 (Pubitemid 28119737)
67. Wlaschek M, Ma W, Jansen-Dürr P, Scharffetter-Kochanek K. Photoaging as a consequence of natural and therapeutic ultraviolet irradiation-studies on PUVA-induced senescence-like growth arrest of human dermal fibroblasts. Exp Gerontol 2003;38:1265-70 (Pubitemid 38041213)
68. Briganti S, Wlaschek M, Hinrichs C, et al. Small molecular antioxidants effectively protect from PUVA-induced oxidative stress responses underlying fibroblast senescence and photoaging. Free Radic Biol Med 2008;45:636-44
69. Stern RS. PUVA follow up study. The risk of melanoma in association with long-term exposure to PUVA. J Am Acad Dermatol 2001;44:755-61 (Pubitemid 32391161)
70. Lindelöf B, Sigurgeirsson B, Tegner E, et al. PUVA and cancer risk: the Swedish follow-up study. Br J Dermatol 1999;141:108-12 (Pubitemid 29333701)
71. Lunder EJ, Stern RS. Merkel-cell carcinomas in patients treated with methoxsalen and ultraviolet A radiation. N Engl J Med 1998;339:1247-8 (Pubitemid 28482140)
72. Halder RM, Battle EF, Smith EM. Cutaneous malignancies in patients treated with psoralen photochemotherapy (PUVA) for vitiligo. Arch Dermatol 1995;131:734-5
73. Buckley DA, Rogers S. Multiple keratoses and squamous carcinoma after PUVA treatment of vitiligo. Clin Exp Dermatol 1996;21:43-5 (Pubitemid 26167419)
74. Takeda H, Mitsuhashi Y, Kondo S. Multiple squamous cell carcinomas in situ in vitiligo lesions after long-term PUVA therapy. J Am Acad Dermatol 1998;38:268-70 (Pubitemid 28100845)
75. Park HS, Lee YS, Chun DK. Squamous cell carcinoma in vitiligo lesion after long-term PUVA therapy. J Eur Acad Dermatol Venereol 2003;17:578-80 (Pubitemid 37138903)
76. Birlea SA, Costin GE, Norris DA. Cellular and molecular mechanisms involved in the action of vitamin D analogs targeting vitiligo depigmentation. Curr Drug Targets 2008;9:345-59 (Pubitemid 351836434)
77. Chiavérini C, Passeron T, Ortonne JP. Treatment of vitiligo by topical calcipotriol. J Eur Acad Dermatol Venereol 2002;16:137-8 (Pubitemid 34460713)
78. Gargoom AM, Duweb GA, Elzorghany AH, et al. Calcipotriol in the treatment of childhood vitiligo. Int J Clin Pharmacol Res 2004;24:11-14 (Pubitemid 39535380)
79. Travis LB, Silverberg NB. Calcipotriene and corticosteroid combination therapy for vitiligo. Pediatr Dermatol 2004;21:495-8 (Pubitemid 39050630)
80. Ameen M, Exarchou V, Chu AC. Topical calcipotriol as monotherapy and in combination with psoralen plus ultraviolet A in the treatment of vitiligo. Br J Dermatol 2001;145:476-9 (Pubitemid 32953707)
81. Goldinger SM, Dummer R, Schmid P, et al. Combination of 308-nm xenon chloride excimer laser and topical calcipotriol in vitiligo. J Eur Acad Dermatol Venereol 2007;21:504-8 (Pubitemid 46454904)
82. Parsad D, Kanwar AJ. Topical vitamin D3 analogues in the treatment of vitiligo. Pigment Cell Melanoma Res 2009;22:487-8
83. Parsad D, Pandhi R, Dogra S, Kumar B. Clinical study of repigmentation patterns with different treatment modalities and their correlation with speed and stability of repigmentation in 352 vitiliginous patches. J Am Acad Dermatol 2004;50:63-7 (Pubitemid 38095653)
84. Park K.K, Liao W, Murase JE. A Review of Monochromatic Excimer Light (MEL) in Vitiligo. Br J Dermatol 2012;Published online 23 Apr 2012; doi: 10.1111/j.1365-2133.2012.11008.x
85. Lotti T, Berti S, Moretti S. Vitiligo therapy. Expert Opin Pharmacother 2009;10:2779-85
86. Spencer JM, Nossa R, Ajmeri J. Treatment of vitiligo with the 308-nm excimer laser: a pilot study. J Am Acad Dermatol 2002;46:727-31
87. Leone G, Iacovelli P, Paro Vidolin A, Picardo M. Monochromatic excimer light 308 nm in the treatment of vitiligo: a pilot study. J Eur Acad Dermatol Venereol 2003;17:531-7 (Pubitemid 37138890)
88. Hofer A, Hassan AS, Legat FJ, et al. The efficacy of excimer laser (308 nm) for vitiligo at different body sites. J Eur Acad Dermatol Venereol 2006;20:558-64
89. Chimento SM, Newland M, Ricotti C, et al. A pilot study to determine the safety and the efficacy of monochromatic excimer light in the treatment of vitiligo. J Drugs Dermatol 2008;7:258-63
90. Casacci M, Thomas P, Pacifico A, et al. Comparison between 308-nm monochromatic excimer light and narrowband UVB phototherapy (311-313 nm) in the treatment of vitiligo-a multicentre controlled study. J Eur Acad Dermatol Venereol 2007;21:956-63 (Pubitemid 47103727)
91. Oh SH, Kim T, Jee H, et al. Combination treatment of non-segmental vitiligo with a 308-nm xenon chloride excimer laser and topical high-concentration tacalcitol: a prospective, single-blinded, paired, comparative study. J Am Acad Dermatol 2011;65:428-30
92. Passeron T, Ostovari N, Zakaria W, et al. Topical tacrolimus and the 308-nm excimer laser: a synergistic combination for the treatment of vitiligo. Arch Dermatol 2004;140:1065-9 (Pubitemid 39223113)
93. Menchini G, Tsoureli-Nikita E, Hercogova J. Narrowband UV-B microphototherapy: a new treatment of vitiligo. J Eur Acad Dermatol Venereol 2003;17:171-7 (Pubitemid 36416783)
94. Kim SM, Lee HS, Hann SK. The efficacy of low-dose oral corticosteroids in the treatment of vitiligo patients. Int J Dermatol 1999;38:546-50 (Pubitemid 29331937)
95. Radakovic-Fijan S, Fürnsinn-Friedl AM, Hönigsmann H, et al. Oral dexamethasone pulse treatment for vitiligo. J Am Acad Dermatol 2001;44:814-17 (Pubitemid 32391170)
96. Pasricha JS, Khaitan BK. Oral mini-pulse therapy with betamethasone in vitiligo patients having extensive or fast-spreading disease. Int J Dermatol 1993;32:753-7 (Pubitemid 23326995)
97. Patel NS, Paghdal KV, Cohen GF. Advanced treatment modalities for vitiligo. 2012;38:381-91
98. Pianigiani E, Andreassi A, Andreassi L. Autografts and cultured epidermis in the treatment of vitiligo. Clin Dermatol 2005;23:424-9 (Pubitemid 40968116)
99. Chen YF, Yang PY, Hu DN, et al. Treatment of vitiligo by transplantation of cultured pure melanocyte suspension: analysis of 120 cases. J Am Acad Dermatol 2004;51:68-74
100. Njoo MD, Westerhof W, Bos JD, Bossuvt PM. A systematic review of autologous transplantation methods in vitiligo. Arch Dermatol 1998;134:1543-9 (Pubitemid 29009254)
101. Fongers A, Wolkerstorfer A, Nieuweboer-Krobotova L, et al. Long-term results of 2-mm punch grafting in patients with vitiligo vulgaris and segmental vitiligo: effect of disease activity. Br J Dermatol 2009;161:1105-11
102. El-Zawahry BM, Zaki NS, Bassiouny DA, et al. Autologous melanocyte-keratinocyte suspension in the treatment of vitiligo. J Eur Acad Dermatol Venereol 2011;25:215-20
103. Pandya V, Parmar KS, Shah BJ, Bilimoria FE. A study of autologous melanocyte transfer in treatment of stable vitiligo. Indian J Dermatol Venereol Leprol 2005;71:393-7 (Pubitemid 41769421)
104. Pianigiani E, Risulo M, Andreassi A, et al. Autologous epidermal cultures and narrow-band ultraviolet B in the surgical treatment of vitiligo. Dermatol Surg 2005;31:155-9 (Pubitemid 40990942)
105. Chen YF, Yang PY, Hu DN, et al. Treatment of vitiligo by transplantation of cultured pure melanocyte suspension: analysis of 120 cases. J Am Acad Dermatol 2004;51:68-74
106. Schallreuter KU, Wood JM, Berger J. Low catalase levels in the epidermis of patients with vitiligo. J Invest Dermatol 1991;97:1081-5
107. Schallreuter KU, Wood JM, Lemke KR, et al. Treatment of vitiligo with a topical application of pseudocatalase and calcium in combination with short-term UVB exposure: a case study on 33 patients. Dermatology 1995;190:223-9
108. Schallreuter KU, Moore J, Behrens-Williams S, et al. Rapid initiation of repigmentation in vitiligo with Dead Sea climatotherapy in combination with pseudocatalase (PC-KUS). Int J Dermatol 2002;41:482-7 (Pubitemid 35021486)
109. Schallreuter KU, Krüger C, Würfel BA, et al. From basic research to the bedside: efficacy of topical treatment with pseudocatalase PC-KUS in 71 children with vitiligo. Int J Dermatol 2008;47:743-53 (Pubitemid 352016092)
110. Sakai Y, Fujita K, Sakai H, Mizuno K. Prostaglandin E2 regulates the expression of basic fibroblast growth factor messenger RNA in normal human fibroblasts. Kobe J Med Sci 2001;47:35-45 (Pubitemid 32862069)
111. Puri N, van der Weel MB, de Wit FS, et al. Basic fibroblast growth factor promotes melanin synthesis by melanocytes. Arch Dermatol Res 1996;288:633-5 (Pubitemid 26335342)
112. Parsad D, Pandhi R, Dogra S, et al. Topical prostaglandin analog (PGE2) in vitiligo-a preliminary study. Int J Dermatol 2002;41:942-5 (Pubitemid 36075252)
113. Kapoor R, Phiske MM, Jerajani HR. Evaluation of safety and efficacy of topical prostaglandin E2 in treatment of vitiligo. Br J Dermatol 2009;160:861-3
114. Schallreuter KU, Chavan B, Rokos H, Levenig C. Decreased phenylalanine uptake and turnover in patients with vitiligo. Mol Genet Metab 2005;86:S27-33 (Pubitemid 41771107)
115. Wolff K, Goldsmith LA, Katz SI, et al. Fitzpatrick's dermatology in general medicine. 7th edition. McGraw-Hill; New York: 2008
116. Camacho F, Mazuecos J. Treatment of vitiligo with oral and topical phenylalanine: 6 years of experience. Arch Dermatol 1999;135:216-17 (Pubitemid 29098382)
117. Greiner D, Ochsendorf FR, Milbradt R. Vitiligo therapy with phenylalanine/UVA. Catamnestic studies after five years. Hautarzt 1994;45:460-3 (Pubitemid 24232639)
118. van den Boorn JG, Melief CJ, Luiten RM. Monobenzone-induced depigmentation: from enzymatic blockade to autoimmunity. Pigment Cell Melanoma Res 2011;24:673-9
119. AlGhamdi KM, Kumar A. Depigmentation therapies for normal skin in vitiligo universalis. J Eur Acad Dermatol Venereol 2011;25:749-57
120. Bolognia JL, Lapia BK, Somma S. Depigmentation therapy. Dermatol Ther 2001;14:29-34 (Pubitemid 32246878)
121. Rao J, Fitzpatrick RE. Use of the Q-switched 755-nm alexandrite laser to treat recalcitrant pigment after depigmentation therapy for vitiligo. Dermatol Surg 2004;30:1043-5 (Pubitemid 38890917)
122. Kasraee B, Fallahi MR, Ardekani GS, et al. Retinoic acid synergistically enhances the melanocytotoxic and depigmenting effects of monobenzylether of hydroquinone in black guinea pig skin. Exp Dermatol 2006;15:509-14 (Pubitemid 43834485)
123. Gupta D, Kumari R, Thappa DM. Depigmentation therapies in vitiligo. Indian J Dermatol Venereol Leprol 2012;78:49-58
124. Njoo MD, Vodegel RM, Westerhof W. Depigmentation therapy in vitiligo universalis with topical 4-methoxyphenol and the Q-switched ruby laser. J Am Acad Dermatol 2000;42:760-9 (Pubitemid 30252879)
125. Di Nuzzo S, Masotti A. Depigmentation therapy in vitiligo universalis with cryotherapy and 4-hydroxyanisole. Clin Exp Dermatol 2010;35:215-16
126. Carlie G, Ntusi NB, Hulley PA, Kidson SH. KUVA (khellin plus ultraviolet A) stimulates proliferation and melanogenesis in normal human melanocytes and melanoma cells in vitro. Br J Dermatol 2003;149:707-17 (Pubitemid 37411990)
127. Hofer A, Kerl H, Wolf P, et al. Long-term results in the treatment of vitiligo with oral khellin plus UVA. Eur J Dermatol 2001;11:225-9 (Pubitemid 32472674)
128. Valkova S, Trashlieva M, Christova P. Treatment of vitiligo with local khellin and UVA: comparison with systemic PUVA. Clin Exp Dermatol 2004;29:180-4 (Pubitemid 38367205)
129. de Leeuw J, Assen YJ, van der Beek N, et al. Treatment of vitiligo with khellin liposomes, ultraviolet light and blister roof transplantation. J Eur Acad Dermatol Venereol 2011;25:74-81
130. Saraceno R, Nisticò SP, Capriotti E, Chimenti S. Monochromatic excimer light 308 nm in monotherapy and combined with topical khellin 4% in the treatment of vitiligo: a controlled study. Dermatol Ther 2009;22:391-4
131. Jain A, Mal J, Mehndiratta V, et al. Study of oxidative stress in vitiligo. Indian J Clin Biochem 2011;26:78-81
132. (2) and impaired cytokine pattern in cultured keratinocytes and blood of vitiligo patients. Antioxid Redox Signal 2010;13:607-20
133. Dell'Anna ML, Ottaviani M, Bellei B, et al. Membrane lipid defects are responsible for the generation of reactive oxygen species in peripheral blood mononuclear cells from vitiligo patients. J Cell Physiol 2010;223:187-93
134. Bhattacharya SK, Dutta AK, Mandal SB, Chatterjee A. Ascorbic acid in vitiligo. Indian J Dermatol 1981;26:4-11
135. Akyol M, Celik VK, Ozcelik S, et al. The effects of vitamin E on the skin lipid peroxidation and the clinical improvement in vitiligo patients treated with PUVA. Eur J Dermatol 2002;12:24-6 (Pubitemid 34131134)
136. Schallreuter KU, Rokos H. Vitix-a new treatment for vitiligo? Int J Dermatol 2005;44:969-70
137. Gonzalez S, Pathak MA, Cuevas J, et al. Topical or oral administration with an extract of polypodium leucotomos prevents acute sunburn and psoralen-induced phototoxic reactions as well as depletion of Langerhans cells in human skin. Photodermatol Photoimmunol Photomed 1997;13:50-60 (Pubitemid 27445908)
138. Middelkamp-Hup MA, Bos JD, Rius-Diaz F, et al. Treatment of vitiligo vulgaris with narrowband UVB and oral polypodium leucotomos extract: a randomized double-blind placebo-controlled study. J Eur Acad Dermatol Venereol 2007;21:942-50 (Pubitemid 47103725)
139. Szczurko O, Shear N, Taddio A, Boon H. Ginkgo biloba for the treatment of vitilgo vulgaris: an open label pilot clinical trial. BMC Complement Altern Med 2011;11:21
140. Garcia F, Pivel JP, Guerrero A, et al. Phenolic components and antioxidant activity of fernblock, an aqueous extract of the aerial parts of the fern polypodium leucotomos. Methods Find Exp Clin Pharmacol 2006;28:157-60 (Pubitemid 43938538)
141. Jańczyk A, Garcia-Lopez MA, Fernandez-Peñas P, et al. A Polypodium leucotomos extract inhibits solar-simulated radiation-induced TNF-alpha and iNOS expression, transcriptional activation and apoptosis. Exp Dermatol 2007;16:823-9 (Pubitemid 47377647)
142. Zattra E, Coleman C, Arad S, et al. Polypodium leucotomos extract decreases UV-induced Cox-2 expression and inflammation, enhances DNA repair, and decreases mutagenesis in hairless mice. Am J Pathol 2009;175:1952-61
143. Dell'Anna ML, Mastrofrancesco A, Sala R, et al. Antioxidants and narrow band-UVB in the treatment of vitiligo: a double-blind placebo controlled trial. Clin Exp Dermatol 2007;32:631-6 (Pubitemid 47609756)
144. Jayanth DP, Pai BS, Shenoi SD, Balachandran C. Efficacy of antioxidants as an adjunct to photochemotherapy in vitiligo: a case study of 30 patients. Indian J Dermatol Venereol Leprol 2002;68:202-5 (Pubitemid 44057926)
145. van Geel NA, Mollet IG, De Schepper S, et al. First histopathological and immunophenotypic analysis of early dynamic events in a patient with segmental vitiligo associated with halo nevi. Pigment Cell Melanoma Res 2010;23:375-84
146. Anbar T-D, Abdel-Raouf H, Awad SS, Ragaie MH. Perifollicular inflammatory infiltrate in vitiligo. Int J Dermatol 2011;50:234-7
147. Anbar TS, Abdel-Raouf H, Awad SS, et al. Presence of eosinophils in the inflammatory infiltrate of nonsegmental vitiligo: a retrospective study. Clin Exp Dermatol 2009;34:e496-7
148. Wang CQ, Cruz-Inigo AE, Fuentes-Duculan J, et al. Th17 cells and activated dendritic cells are increased in vitiligo lesions. PLoS One 2011;6:e18907
149. Bassiouny DA, Shaker O. Role of interleukin-17 in the pathogenesis of vitiligo. Clin Exp Dermatol 2011;36:292-7
150. Ben Ahmed M, Zaraa I, Rekik R, et al. Functional defects of peripheral regulatory T lymphocytes in patients with progressive vitiligo. Pigment Cell Melanoma Res 2012;25:99-109
151. Gupta AK, Ellis CN, Nickoloff BJ, et al. Oral cyclosporine in the treatment of inflammatory and non inflammatory dermatoses. A clinical and immunopathologic analysis. Arch Dermatol 1990;126:339-50 (Pubitemid 20094674)
152. Gokhale BB. Cyclophosphamide and vitiligo. Int J Dermatol 1979;18:92
153. Radmanesh M, Saedi K. The efficacy of combined PUVA and low-dose azathioprine for early and enhanced repigmentation in vitiligo patients. J Dermatolog Treat 2006;17:151-3 (Pubitemid 44147831)
154. Sandra A, Pai S, Shenoi SD. Unstable vitiligo responding to methotrexate. Indian J Dermatol Venereol Leprol 1998;64:309
155. Simón JA, Burgos-Vargas R. Vitiligo improvement in a patient with ankylosing spondylitis treated with infliximab. Dermatology 2008;216:234-5 (Pubitemid 351416724)
156. Alghamdi KM, Khurrum H, Rikabi A. Worsening of vitiligo and onset of new psoriasiform dermatitis following treatment with infliximab. J Cutan Med Surg 2011;15:280-4
157. Ram'irez-Hernández M, Marras C, Mart'inez-Escribano JA. Infliximab-induced vitiligo. Dermatology 2005;210:79-80 (Pubitemid 39656730)
158. Smith DI, Heffernan MP. Vitiligo after the resolution of psoriatic plaques during treatment with adalimumab. J Am Acad Dermatol 2008;58:S50-2
159. Posada C, Flórez A, Batalla A, et al. Vitiligo during treatment of Crohn's disease with adalimumab: adverse effect or co-occurrence? Case Rep Dermatol 2011;3:28-31
160. Rigopoulos D, Gregoriou S, Larios G, et al. Etanercept in the treatment of vitiligo. Dermatology 2007;215:84-5
161. Campanati A, Giuliodori K, Ganzetti G, et al. A patient with psoriasis and vitiligo treated with etanercept. Am J Clin Dermatol 2010;11:S46-8
162. Alghamdi KM, Khurrum H, Taieb A, Ezzedine K. Treatment of generalized vitiligo with anti-TNF-a agents. J Drugs Dermatol 2012;11:534-9
163. Parsad D, Kanwar A. Oral minocycline in the treatment of vitiligo-a preliminary study. Dermatol Ther 2010;23:305-7
164. Song X, Xu A, Pan W, et al. Minocycline protects melanocytes against H2O2-induced cell death via JNK and p38 MAPK pathways. Int J Mol Med 2008;22:9-16
165. Barnetson RS, Ooi TK. Zhuang L, et al. [Nle4-D-Phe7]-alphamelanocyte- stimulating hormone significantly increased pigmentation and decreased UV damage in fair-skinned Caucasian volunteers. J Invest Dermatol 2006;126:1869-78 (Pubitemid 44086522)
166. Harms J, Lautenschlager S, Minder CE, Minder EI. An alpha-melanocyte- stimulating hormone analogue in erythropoietic protoporphyria. N Engl J Med 2009;360:306-7